Literature DB >> 10972736

Survival of mycobacterial species in aerosols generated from artificial saliva.

M S Lever1, A Williams, A M Bennett.   

Abstract

Tuberculosis is transmitted primarily by the aerosol route and the aim of this study was to measure the ability of pathogenic mycobacteria to survive in aerosols generated from artificial saliva. Aerosols of Mycobacterium avium, Mycobacterium intracellulare and Mycobacterium tuberculosis were generated and maintained in air under controlled conditions using a Henderson apparatus and a rotating drum. There were no differences in aerosol survival between the three species, and all had a poor survival rate over a period of 1 h. These data confirm epidemiological studies that close and prolonged contact with a TB patient is required for transmission of infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10972736     DOI: 10.1046/j.1365-2672.2000.00807.x

Source DB:  PubMed          Journal:  Lett Appl Microbiol        ISSN: 0266-8254            Impact factor:   2.858


  13 in total

Review 1.  Transmission and Institutional Infection Control of Tuberculosis.

Authors:  Edward A Nardell
Journal:  Cold Spring Harb Perspect Med       Date:  2015-08-20       Impact factor: 6.915

2.  Bioaerosol mass spectrometry for rapid detection of individual airborne Mycobacterium tuberculosis H37Ra particles.

Authors:  Herbert J Tobias; Millie P Schafer; Maurice Pitesky; David P Fergenson; Joanne Horn; Matthias Frank; Eric E Gard
Journal:  Appl Environ Microbiol       Date:  2005-10       Impact factor: 4.792

3.  Assessing the airborne survival of bacteria in populations of aerosol droplets with a novel technology.

Authors:  Mara Otero Fernandez; Richard J Thomas; Natalie J Garton; Andrew Hudson; Allen Haddrell; Jonathan P Reid
Journal:  J R Soc Interface       Date:  2019-01-31       Impact factor: 4.118

4.  Characterisation of a live Salmonella vaccine stably expressing the Mycobacterium tuberculosis Ag85B-ESAT6 fusion protein.

Authors:  Lindsay J Hall; Simon Clare; Derek Pickard; Simon O Clark; Dominic L F Kelly; Moataz Abd El Ghany; Christine Hale; Jes Dietrich; Peter Andersen; Philip D Marsh; Gordon Dougan
Journal:  Vaccine       Date:  2009-09-13       Impact factor: 3.641

5.  Oral vaccination of guinea pigs with a Mycobacterium bovis bacillus Calmette-Guerin vaccine in a lipid matrix protects against aerosol infection with virulent M. bovis.

Authors:  Simon Clark; Martin L Cross; Allan Nadian; Julia Vipond; Pinar Court; Ann Williams; R Glyn Hewinson; Frank E Aldwell; Mark A Chambers
Journal:  Infect Immun       Date:  2008-06-02       Impact factor: 3.441

6.  Transformative Approach To Investigate the Microphysical Factors Influencing Airborne Transmission of Pathogens.

Authors:  Mara Otero Fernandez; Richard J Thomas; Henry Oswin; Allen E Haddrell; Jonathan P Reid
Journal:  Appl Environ Microbiol       Date:  2020-11-10       Impact factor: 4.792

Review 7.  Aerobiology: Experimental Considerations, Observations, and Future Tools.

Authors:  Allen E Haddrell; Richard J Thomas
Journal:  Appl Environ Microbiol       Date:  2017-08-17       Impact factor: 4.792

Review 8.  The impact of COVID-19 on tuberculosis: challenges and opportunities.

Authors:  Surya Kant; Richa Tyagi
Journal:  Ther Adv Infect Dis       Date:  2021-06-09

9.  Assessment of Mycobacterium bovis deleted in p27-p55 virulence operon as candidate vaccine against tuberculosis in animal models.

Authors:  María V Bianco; Simon Clark; Federico C Blanco; Sergio Garbaccio; Elizabeth García; Angel A Cataldi; Ann Williams; Fabiana Bigi
Journal:  Biomed Res Int       Date:  2014-01-21       Impact factor: 3.411

10.  Non-replicating Mycobacterium tuberculosis elicits a reduced infectivity profile with corresponding modifications to the cell wall and extracellular matrix.

Authors:  Joanna Bacon; Luke J Alderwick; Jon A Allnutt; Evelina Gabasova; Robert Watson; Kim A Hatch; Simon O Clark; Rose E Jeeves; Alice Marriott; Emma Rayner; Howard Tolley; Geoff Pearson; Graham Hall; Gurdyal S Besra; Lorenz Wernisch; Ann Williams; Philip D Marsh
Journal:  PLoS One       Date:  2014-02-06       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.